Sentences with word «lenalidomide»

The entire study «Use of Lenalidomide in 5q - Myelodysplastic Syndrome Provides Novel Treatment Prospects in Management of Pulmonary Sarcoidosis» can be viewed in the August issue of CHEST.

While several clinical trials have demonstrated that maintenance therapy with lenalidomide reduces the risk of disease progression in patients with multiple myeloma, there have been no definitive results regarding overall survival.

At seven years, 62 % of those treated with maintenance lenalidomide had survived, compared to 50 % of those in the control group.

The KEYNOTE - 183, KEYNOTE - 185, and KEYNOTE - 023 trials evaluating the programmed death 1 (PD - 1) inhibitor pembrolizumab in combination with pomalidomide or lenalidomide for patients with multiple myeloma were placed on hold due to the increase in deaths on the pembrolizumab arms of KEYNOTE - 183 and KEYNOTE - 185 trials.

«Case study reveals therapy to reduce sarcoidosis symptoms in 5q - myelodysplastic syndrome: Use of lenalidomide in 5q - myelodysplastic syndrome provides new hope in sarcoidosis therapy.»

After several hearings by different review panels the application for Lenalidomide funding was rejected.

A case study published in the August issue of the journal CHEST found lenalidomide treatments may have an immediate effect in the treatment of sarcoidosis - related symptoms.

The trials pair the oral drugs lenalidomide and dexamethasone with other agents, each of which exploits a different vulnerability in tumor cells.

While some previous studies found that maintenance lenalidomide after autologous hematopoietic stem cell transplant improved overall survival for newly diagnosed multiple myeloma patients, others showed no benefit to this approach.

For this analysis, 605 patients with newly diagnosed multiple myeloma and treated with continuous lenalidomide (brand name Revlimid) following autologous stem cell transplant were compared to 604 patients who were treated with placebo or no maintenance.

The case is the first of its kind to report the potential effects of lenalidomide as a therapeutic option in patients with pulmonary sarcoidosis.

Lenalidomide + Plerixafor in Previously Treated Chronic Lymphocytic Leukemia (CLL).

Mesenchymal stromal cells from patients with myelodyplastic syndrome display distinct functional alterations that are modulated by lenalidomide.

Impact of lenalidomide on the functional properties of human mesenchymal stromal cells.

These results are indicative that that the risks of treatment with the investigational drug plus pomalidomide or lenalidomide outweighed any potential benefit.

In the trial, patients receiving all three drugs had a 35 percent improvement in progression - free survival — the length of time before the disease begins to worsen — compared to those receiving lenalidomide and dexamethasone alone.

Upon receiving two cycles of treatment with lenalidomide, the patient's breathlessness, fatigue, daily activity, and quality of life showed significant improvement, and her lung function testing demonstrated a remarkable increase in vital capacity.

It was common ground that without the chance of attempting the life - extending properties of Lenalidomide in conjunction with one or two other drugs, which were themselves uncontroversial, the claimant's life expectancy was limited to the progress of the myeloma.

A combined phase 1 and phase 2 trial of lenalidomide / dexamethasone plus a breakthrough antibody therapy called daratumumab (Darzalex ™).

A phase 3 trial of lenalidomide / dexamethasone plus ixazomib (Ninlaro ®), a «proteasome inhibitor» that blocks the ability of cancer cells to reuse certain proteins.

A phase 3 trial of lenalidomide / dexamethasone with elotuzumab (Empliciti ™), an antibody therapy that attacks myeloma cells directly and spurs the immune system to launch an attack of its own.

Treatment with the three - drug regimen resulted in a 30 percent reduction in the risk that the disease would progress over a three - year period, compared to a course of lenalidomide and dexamethasone alone.

Patients received a tandem of lenalidomide, a drug that kills tumor cells, blocks blood vessel growth, and acts on the immune system, and dexamethasone, an anti-inflammatory agent, plus one of three new agents:

The study, «Lenalidomide (LEN) maintenance (MNTC) after high - dose melphalan and autologous stem cell transplant (ASCT) in multiple myeloma (MM): A meta - analysis (MA) of overall survival (OS),» is ASCO 2016 abstract no. 8001 and will be discussed during the Hematologic Malignancies — Plasma Cell Dyscrasia oral abstract session Friday, June 3.

«Lenalidomide maintenance following autologous stem cell transplant can now be considered a standard of care for people with multiple myeloma,» says Dr. McCarthy, senior author on the meta - analysis and Principal Investigator of the U.S. study, CALGB (Alliance) 100104.

«Lenalidomide maintenance therapy improves overall survival for patients with multiple myeloma.»

Continuous treatment with lenalidomide / dexamethasone significantly improved survival in patients with transplant - ineligible newly diagnosed multiple myeloma.

Patients have received bortezomib, lenalidomide, and thalidomide as prior treatments.

Lenalidomide is a capsule that is taken by mouth.

Standard treatments for symptomatic myeloma include chemotherapy with drugs like bortezomib (Velcade ®), lenalidomide (Revlimid ®), ixazomib (Ninlaro ®), and panobinostat (Farydak ®), autologous stem cell transplantation, and, in some cases, radiation therapy.

For some MDS patients, lenalidomide can improve anemia and reduce or eliminate the need for blood transfusions.

Preliminary findings presented at ASH suggest a «favorable emerging clinical profile» for once weekly administration of MLN9708 in combination with lenalidomide and dexamethasone in patients with newly diagnosed multiple myeloma.

New treatment regimens using thalidomide or lenalidomide are also being studied.

Thalidomide, lenalidomide, and pomalidomide are immunomodulators used to treat multiple myeloma and other plasma cell neoplasms.

Emergence and evolution of TP53 mutations are key features of disease progression in myelodysplastic patients with lower - risk del (5q) treated with lenalidomide

At present, he is leading multiple efforts studying the use of new agents and pioneered the development of lenalidomide, bortezomib, and dexamethasone (so called RVD), which is now widely used in the upfront treatment of multiple myeloma.

His primary research interest is in novel therapies for myeloma, and he has been at the forefront of the clinical development of bortezomib, lenalidomide, and most recently pomalidomide.

Tim was treated with lenalidomide (Revlimid) and dexamethasone, a chemotherapy regimen commonly used to treat multiple myeloma.

Represented Dr. Reddy's Laboratories (DRL) against Celgene in Hatch - Waxman patent infringement litigation involving DRL's abbreviated new drug application to the FDA for a generic version of Revlimid (lenalidomide).

(i) they misunderstood the effectiveness of lenalidomide: with the result that they could not rationally assess its «cost effectiveness»;

(ii) they had failed to understand that the actual sums sought were for four cycles, with the potential for a total of 11 cycles if the claimant responded to lenalidomide; that, if he did not respond, the treatment would probably not be continued so that further cost would not arise;